接受放疗与槲寄生(Viscum album L.)治疗的肺癌患者生活质量评估:一项真实世界数据研究
这项真实世界数据研究利用注册数据,以EORTC QLQ-C30量表评估112例原发性肺癌患者(92%为非小细胞肺癌,中位年龄70岁)在诊断时及12个月后的生活质量变化。接受放疗联合槲寄生(VA)治疗的患者在疼痛(改善27分,p=0.006)和恶心/呕吐(改善17分,p=0.005)方面显著改善;接受指南治疗但无放疗、联合VA的患者在角色、躯体、认知和社会功能方面显著改善15至21分。作者认为VA附加治疗对肺癌患者生活质量有支持作用。
要点
- 放疗联合槲寄生(VA)治疗患者疼痛改善27分(p=0.006)、恶心/呕吐改善17分(p=0.005)。
- 指南治疗无放疗但联合VA患者角色、躯体、认知和社会功能改善15至21分(p=0.03至0.04)。
- 共112例原发性肺癌患者完成基线和12个月EORTC QLQ-C30问卷。
核心结论
- 作者认为槲寄生(VA)附加治疗对肺癌患者的生活质量具有支持作用,尤其与放疗联合时观察到疼痛和恶心/呕吐的显著减轻。
研究设计与样本
- 研究为真实世界数据研究,使用注册数据,纳入112例原发性肺癌患者(全部分期,92%为非小细胞肺癌,中位年龄70岁,ICR:63-75)。
- 采用EORTC QLQ-C30量表评估患者自报生活质量,并进行校正多因素线性回归分析12个月时生活质量变化的相关因素。
主要发现
- 接受放疗联合VA治疗的患者12个月时疼痛评分改善27分(p=0.006),恶心/呕吐评分改善17分(p=0.005)。
- 接受指南治疗但无放疗、联合VA的患者12个月时角色功能改善15至21分(p=0.03)、躯体功能(p=0.02)、认知功能(p=0.04)和社会功能(p=0.04)均显著改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lung cancer (LC) is associated with high mortality and poor quality of life (QoL). The disease as well as oncological treatments such as radiation and chemotherapy with adverse effects can impair the QoL of patients. Add-on treatment with extracts of Viscum album L. (white-berry European mistletoe, VA) has been shown to be feasible and safe and to improve the QoL of cancer patients. The aim of this study was to analyze the changes in QoL of LC patients being treated with radiation according to oncological guidelines and add-on VA treatment in a real-world setting. METHODS: A real-world data study was conducted using registry data. Self-reported QoL was assessed by the evaluation of the European Organization of Research and Treatment Health-Related Quality of Life Core Questionnaire scale (EORTC QLQ-C30). Adjusted multivariate linear regression analyses were performed to analyze factors associated with changes in QoL at 12 months. RESULTS: A total of 112 primary LC patients (all stages, 92% non-small-cell lung cancer, median age 70 (ICR: 63-75)), answered the questionnaires at first diagnosis and 12 months later. Assessment of 12 months changes in QoL revealed significant improvement of 27 points for pain (p = 0.006) and 17 points for nausea/vomiting (p = 0.005) in patients who received combined radiation and VA. In addition, significant improvements of 15 to 21 points for role (p = 0.03), physical (p = 0.02), cognitive (p = 0.04), and social functioning (p = 0.04) were observed in guideline treated patients receiving no radiation but add-on VA. CONCLUSIONS: Add-on VA therapy reveals supportive effects for the QoL of LC patients. Particularly in combination with radiation a significant reduction in pain and nausea/ vomiting has been observed. Trial registration The study received ethics approval and was retrospectively registered (DRKS00013335 on 27/11/2017).
引用
- Schad F, Steinmann D, Oei SL, et al. Evaluation of quality of life in lung cancer patients receiving radiation and Viscum album L.: a real-world data study. Radiat Oncol. 2023. PMID: 36879290. doi:10.1186/s13014-023-02234-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。